WATERTOWN, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing novel, integrated drug and delivery solutions for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis,

-- Company Prioritizing ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS); Study Remains on Track, with Full Enrollment Anticipated mid-2023 -- -- Company to Manufacture All Clinical Trial Supply to Leverage its In-House Expertise and Capabilities; Temporarily Pausing

WATERTOWN, Mass. , Sept. 13, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc . (Nasdaq: LYRA) (the Company, Lyra or Lyra Therapeutics ), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and

 21-point (37%) mean improvement in SNOT-22 total score at six weeks during the uncontrolled Part 1 stage of the 24-week BEACON trial First patient dosed in the randomized, Part 2 stage of the BEACON trial The LYR-220 program in post-surgical patients is in addition to LYR-210 which is in phase III

Significantly more patients with moderate/severe symptoms of chronic rhinosinusitis at baseline improved to mild/no symptoms at week 24 after treatment with LYR-210 (7500μg) compared to control The three cardinal symptoms composite score shown to correlate with the well-established SNOT-22 scores

ENLIGHTEN II is the second of two Phase 3 trials enrolling surgically-naïve CRS patients in the Global ENLIGHTEN clinical program. WATERTOWN, Mass. , Sept. 8, 2022 /PRNewswire/ --  Lyra Therapeutics , Inc.  (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage therapeutics company leveraging its

WATERTOWN, Mass. , Sept. 6, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc . (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages

WATERTOWN, Mass. , Aug. 29, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

Pivotal ENLIGHTEN Phase 3 clinical program and BEACON Phase 2 clinical trial targeting a broad spectrum of chronic rhinosinusitis  (CRS) patients, continued enrollment Industry leader Richard Nieman , MD, appointed Chief Medical Officer In April 2022 , secured $96.3 million in net proceeds in an

Industry leader with substantial U.S. and global experience in drug development and medical affairs joins Lyra as the Company's late-stage product candidates advance in the clinic WATERTOWN, Mass. , July 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc .